Here are three things to know:
- The acquisition deal includes an upfront payment of approximately $360 million for the 90% of SoniVie not already owned by Boston Scientific, with an additional $180 million contingent on regulatory milestones, according to a March 1 news release from the company.
- The TIVUS system uses ultrasound energy to target nerve activity linked to hypertension, potentially offering an alternative or adjunct to existing blood pressure treatments.
- The acquisition is expected to close in the first half of 2025 and is pending regulatory approval.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
